Research article published in Cells
We would like to introduce a new publication using the STAM™ model presented by our client NeuroVive in Cells.
NeuroVive
Title: “Evaluation of NV556, a Novel Cyclophilin Inhibitor, as a Potential Antifibrotic Compound for Liver Fibrosis”
This paper analyzes the anti-fibrotic effect of NV556 in vivo. NV556 is an inhibitor of Cyclophilin, which is thought to be involved in the development of fibrosis.
* NAFLD activity score, and fibrosis in STAM (Fig.2 F, G)
Inhibition of Fibrosis
Our STAM model was used as an in vivo model for NASH.
Although administration of NV556 did not significantly alter hepatic triglyceride, cholesterol, or the NALFD activity score, pathological evaluation using Sirius red staining confirmed that NV556 improved fibrosis.
These results suggest that NV556 acts on extracellular matrix (ECM) deposition and exerts anti-fibrotic potential. Although clinical trials of NV556 are not yet decided, it is expected to show similar results in future clinical trials.
We believe that the STAM model is an excellent platform for new drug development and can support a smooth progression to clinical trials. SMC offers multiple NASH models in addition to STAM, such as the MCD model also used in this paper.
More than just NASH, we have an extensive line-up of models for other inflammatory and fibrotic diseases as well.
We are currently running a campaign in which we are offering to include a Vehicle control group for free when conducting a preliminary study using any of our disease models. The offer is available until March 31st, so if you would like to take advantage of our limited campaign, please get in touch soon!
If you have any questions, or would like any more information on any of our models or services, please don’t hesitate to contact us.